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Abstract: Teucrium species have been used in folk medicine as antidiabetic, antiinflammatory, antiulcer, and antibac-
terial agents. We have explored in vitro antidiabetic impacts of 2 natural diterpenoids, alysine A and alysine B, isolated
from Teucrium alyssifolium. The lactate dehydrogenase (LDH) cytotoxicity assay, glucose uptake test, glucose utilization
(glycogen content) test, glucose transport test, glucose absorption (α -glucosidase activity) test, insulin secretion test,
RNA isolation and cDNA synthesis assay, qPCR quantification assays, and statistical analyses were carried out in the
present study. Alysine A exerted the following effects at non-cytotoxic doses:
• Enhanced the glucose uptake, as much as the insulin in the C2C12, HepG2, and 3T3-L1 cells
• Increased the glycogen content in the C2C12 and HepG2 liver cells, significantly higher than the insulin and
metformin
• Suppressed the alpha-glucosidase and the GLUT2 expression levels in the Caco-2 cells
• Suppressed the SGLT1 and GLUT1-5 expression levels in the Caco-2 cells
• Induced the insulin receptor substrate (IRS)1 and GLUT2 expression levels of the BTC6 pancreatic cells
• Induced the insulin receptor (INSR), IRS2, phosphoinositide 3-kinase (PI3K), GLUT4, and protein kinase (PK)
expression levels of the 3T3-L1 and C2C12 cells
• Increased glucose transport through the Caco-2 cell layer
• Did not influence insulin secretion in the pancreatic BTC6 cells
Consequently, these data strongly emphasized the antidiabetic action of alysine A on the particularly critical model
mechanisms that assume a part in glucose homeostasis, such as glucose uptake, utilization, and storage. Moreover, the
expression level of the essential genes in glucose metabolism and insulin signaling was altered in a way that the results
would be antihyperglycemic. A blend of in vitro and in situ tests affirmed the antihyperglycemic action of alysine A and
its mechanism. Alysine A has exercised significant and positive results on the glucose homeostasis; thus, it is a natural
and pleiotropic antidiabetic agent. Advanced in vivo studies are required to clarify the impact of this compound on
glucose homeostasis completely.
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1. Introduction
The genus Teucrium, a member of the family Lamiaceae, has approximately 300 species worldwide, mostly in
the Mediterranean region. Teucrium is represented by 46 taxa in Turkey, 16 of which are endemic. Teucrium
species have been used in folk medicine as antidiabetic, antiinflammatory, antiulcer, and antibacterial agents
[1]. Studies have shown that Teucrium species demonstrate antimicrobial, antioxidant, and antifungal activities
[2]. The main compounds isolated from Teucrium species to date are clerodane and neoclerodane diterpenes
[3]. Therefore, it can be opined that clerodane and neoclerodane diterpenoids could be responsible for those
activities that Teucrium species exhibit. For this reason, these precious natural diterpenes were obtained by
isolating or synthesizing.
Diabetes mellitus (DM) is a chronic disease that occurs when the insulin hormone that regulates blood
sugar is not sufficiently produced or when the body cannot use insulin efficiently. Hyperglycemia, or high blood
sugar, that occurs when DM is not controlled, leads to severe damage over time, especially in many systems
of the body, such as nerves and blood vessels. It has been reported that 347 million people worldwide have
diabetes [4]. In 2004, about 3.4 million people were reported to have died as a result of high blood sugar [5]
and similar figures for 2010 are estimated. Reflection and estimation studies predict that diabetes will be the
seventh largest cause of death in the world by 2030 [5].
The most common form of diabetes is type 2 DM (T2DM), although there are 3 major forms of diabetes.
In T2DM patients, cells do not respond appropriately to insulin (insulin resistance), resulting in glucose storage
deficiency. Insulin resistance can develop in later ages, especially with long-term high-calorie diets and other
risk factors. Insulin resistance causes a disorder of the complex signaling mechanism between adipose tissue,
pancreatic islets, liver, and skeletal muscle [6–8]. The specific molecular pathology of the disease is not evident;
family history, changes in early development, excessive nutrient intake, obesity, lack of physical activity, and
aging pave the way for disease development. Mitochondrial oxidative metabolism and adenosine triphosphate
production, fatty acid oxidation, proinflammatory signaling, and a change in the development and metabolism
of beta cells can reduce insulin secretion. This can lead to insulin resistance as it impairs insulin signaling [9].
The use of medicinal herbs for the treatment of diabetes extends back to the Ebers Papyrus of 1550 BC
[10]. Despite the discovery and use of insulin and other modern oral hypoglycemic agents, the search for safer
and more efficacious herbal medicines for the treatment of diabetes continues [10]. Because of the high cost
of insulin and lack of medical care, many herbal uses remain an alternative, especially in poor communities.
Teucrium species are characterized as a hypoglycemic adjunct without any detailed and precise knowledge of the
mode of action, without any adverse effects for years on T2DM, especially T. polium [11,12]. With the extract
of Teucrium alyssifolium Stapf, which is endemic to Turkey, its antidiabetic effect was detected during our pilot
screening study in the laboratory. This data suggested the potential antidiabetic effect of T. alyssifolium.
Secondary metabolites acquired from plants, particularly those utilized traditionally, are at the pioneers of
new medicine development in fighting diseases like diabetes. It is known that isolated or synthesized terpenoids
have shown an antidiabetic effect [13–18], as well as antioxidant, anticholinesterase, and opioid receptor activities
[19–21]. In this context, the antihyperglycemic activity of 2 pure diterpenoid compounds, alysine A and alysine
B, previously isolated from T. alyssifolium, an endemic species of Teucrium, was first investigated by in vitro
models.
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2. Materials and methods
2.1. Materials
The following were used in this study: dimethylbiguanide hydrochloride, 3-Isobutyl-1-methylxanthine, 96-well
microplates, (D - (+) - glucose, dexamethasone, dimethyl sulfoxide (DMSO), calcium chloride, L-glutamine,
maltose solution, bovine serum albumin (BSA), insulin solution, and sucrose (Sigma-Aldrich, St. Louis, MO,
USA); EasyScript™plus cDNA synthesis kit and KiloGreen 2X qPCR (MasterMix-KS) (Applied Biological
Materials Inc., BC, Canada); 3T3-L1, C2C12, HepG2, and BTC6 cell lines (LGS Standards GmbH, We-
sel, Germany); For the primers, 50 nmol of Oligo-DNA (GenScript, NJ, USA); Gibco fetal bovine serum
(FBS) (Thermo Fisher Scientific, MA, USA); Dulbecco’s modified Eagle’s medium (DMEM), Dulbecco’s phos-
phate buffered saline (PBS), Eagle’s modified essential medium (EMEM), penicillin-streptomycin mixture,
and trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Lonza Group Ltd., Basel, Switzerland); insulin
enzyme-linked immunosorbent assay (ELISA) kit (EMD Millipore Corp., MA, USA); RNeasy plus mini kit
(74136) (Qiagen Inc., CA, USA); and glucose assay kit, insulin ELISA kit, glycerol 3-phosphate activity kit,
and lactate dehydrogenase (LDH) activity kit (BioVision Inc., CA, USA).
2.2. Cell lines
C2C12 mouse myoblast, 3T3L1 mouse preadipocyte, and BTC6 mouse beta cell lines were grown in DMEM
medium containing 10%, 10%, and 15% inactivated FBS, respectively, and 1% penicillin/streptomycin at 37 ◦C
in a humidified environment containing 5% CO2 . HepG2 human liver and Caco-2 human colon cell lines were
grown in EMEM medium containing 10% and 5% inactivated FBS, respectively, and 1% penicillin/streptomycin
at 37 ◦C in a humidified environment containing 5% CO2 . When the cells reached 80% confluency, they were
removed with a trypsin-EDTA solution, stained with trypan blue, and counted on a Thomacell counting chamber
using the microscope for subculturing.
2.3. Test compounds – alysine A and alysine B
2.3.1. Isolation and purification
Test compounds alysine A and alysine B were isolated from the aerial parts of Teucrium alyssifolium, and
identified as described previously [22]. The plant was macerated with acetone, and the crude acetone extract
was separated over silica gel using hexane, ethyl acetate, and ethanol, respectively. The collected fractions were
further separated on small columns using Si-gel and Sephadex LH-20, in addition to preparative TLC plates.
The structure of the alysine A and alysine B were confirmed based on X-ray diffraction, 1D- and 2D-NMR, and
mass spectral analyses [22] (Figures S1–S10, Table S1), (Figure 1).
2.4. Preparations for use in the test experiments
All of the test compounds were first solubilized in DMSO, with a final concentration of 1 mg/mL, and completed
to the final volume with the growth medium. The DMSO concentration was adjusted to 10% in the final volume.
The dissolved compounds were then aliquoted into small volumes, gassed with nitrogen, and stored at –20 ◦C.
During the experiments, each aliquot was opened and used for testing the activities, and the remaining quantities
were discarded. Thus, the compounds were impaired during the experiments or prevented from being exposed
to oxidation. Hence, deterioration or oxidation of the compounds during the experiments was prevented.
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Figure 1. X-ray spectra of alysine A and alysine B.
2.5. Effect on cell viability
The cells were plated in 96-well plates at 1 × 104 cells/well and supplemented with the appropriate growth
medium to give a total of 200 µL. The cells were allowed to adhere to the plate. Next, the growth medium
was poured off and the test compounds were added into the wells, at various concentrations, along with the
vehicle controls (10% DMSO in growth medium), and incubated for 24 h in a CO2 incubator. At the end of
this period, 100 µL of crystal violet solution (0.5% in 10% EtOH) was added to each well after aspirating the
test compounds, and they were then incubated at room temperature for 10 min. The stain was then washed
out under tap water until the stain was removed. Next, 100 µL of sodium citrate solution (dissolved in 50%
EtOH, 1 M, pH 4.2) was added to the wells and incubated at room temperature for 15 min. The absorbance
values were then measured at 630 nm using an ELISA microplate reader with agitation. The percent survival
was determined using the obtained absorbance values.
2.6. LDH cytotoxicity assay
In addition to crystal violet staining, the LDH activities were measured in the medium where the cells were incu-
bated with the test compounds, if there was any toxic effect on the cells at the concentrations determined. LDH
activities in the medium were determined colorimetrically using the BioVision LDH-cytotoxicity colorimetric
assay kit, as directed by the manufacturer.
2.7. Glucose uptake test
Glucose uptake experiments were performed with the 3T3-L1*, C2C12, and Chang cell lines. For these
experiments, freshly passaged cells were seeded at 4500 cells per well in a 96-well microplate and grown for
48 h. At the end of this period, 8 mM glucose, 0.1% BSA, and the test compound or vehicle (10% DMSO in
the medium) or positive controls (1 µM insulin and 1 µM metmorfin) were added to the appropriate well and
incubated for an additional 2 h. At the end of the incubation period, 10 µL of the medium was transferred from
each well into a new 96-well microplate. The final volume was brought to 200 µL by adding glucose reactant,
and the absorbances were recorded at 450 nm using a microplate reader after 30 min incubation at 37 ◦C. The
glucose assay was determined by essentially using the BioVision colorimetric glucose assay kit, following the
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manufacturer’s instructions.
The *3T3-L1 preadipocytes were transformed into adipocytes for use in the glucose uptake tests.
Adipocyte differentiation was induced by adding 10 µg/mL insulin, 10−8 M DEX, and 0.1 mM isobutyl-
methylxanthine to the growth medium of the freshly passaged 3T3-L1 cells at the end of the first day. At the
end of the fifth day, the cells were washed and transferred to normal growth medium. Cell differentiation was
determined using the highly sensitive BioVision glycerol-3-phosphate dehydrogenase (G3PDH) activity colori-
metric assay kit, as directed by the manufacturer, since G3PDH mRNA, protein, and activity are used as an
indicator of adipocyte differentiation.
2.8. Glucose utilization (glycogen content) test
These experiments were performed with C2C12 muscle and HepG2 liver cell lines that had a glycogen storage
capacity. The cells were grown under standard conditions until the day of the experiment. On the day of the
experiment, the cells were washed with PBS at 37 ◦C, to remove the residues of the glucose and medium,
and incubated for 2 h in serum-free medium. The cells were then incubated with the growth medium, vehicle,
positive control agent (1 µM insulin), or test compounds. At the end of the incubation time, the cells were
trypsinized and counted using a hemocytometer to remove 1.0 × 106 cells, which were then centrifuged (4 min
at 5 ◦C, 800 × g) . The resulting pellet was resuspended by homogenization in 200 µL of distilled water on ice
and then boiled for 5 min to inactivate the glycogen degrading enzymes. The boiled suspension was then spun
at 18,000 × g for 10 min, and 25 µL of the supernatant was transferred to 96-well plates, and the glycogen
content was determined in a colorimetric manner, in accordance with the manufacturer’s instructions, with the
BioVision glycogen assay kit.
2.9. Glucose transport test
These experiments were performed with the Caco-2 cell line. The glucose transport activity of the Caco-2
cell lines was performed with the previous method. For the transport experiments, the cells were plated in
polycarbonate-filtered cell culture plates (Corning Transwell, 24-mm diameter, 3 µm), as described by [23],
and the cells were left to differentiate for 15–17 days after confluency; the medium was regularly changed 3
times a week. The integrity of the Caco-2 cell monolayers and the full development of the tight junctions were
monitored by microscopic examination. In order to measure the glucose transport across the Caco-2 monolayer,
both sides of the transwells were washed with buffer (20 mM Tris-HCl, pH 7.4 containing 80 mM NaCl, 100
mM mannitol, 3 mM K2HPO4 , 1 mM CaCl2 , and 1 mg/mL BSA) to remove any traces of glucose. The
monolayer was then subjected to preincubation in the incubation buffer at 37 ◦C for 1 h and replaced with
fresh incubation buffer just before the transport assay. The transport experiment was initiated by the addition
of 25 mM D-glucose plus the vehicle control, positive control (1 µM insulin), or test compounds to the apical
side of the chamber. Next, 10 µL of the samples were taken at 0, 30, and 60 min from the apical and basolateral
sides, and replaced with glucose-free incubation solution. Glucose levels in the samples were determined using
the BioVision colorimetric glucose assay kit, according to the manufacturer’s instructions.
2.10. Glucose absorption (α-glucosidase activity) test
The assay was performed with the Caco-2 cell line, as described by [24], under the described conditions given
above in Section 4.7. To determine the alpha-glycosidase activity in the Caco-2 cells, the trans-wells were
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washed with PBS. The monolayer was subjected to preincubation in PBS at 37 ◦C for 1 h. The experiment was
initiated by changing the apical medium with 28 µM maltose, 28 µM sucrose, and PBS containing a vehicle,
positive control (1 µM glibenclamide), or the test compounds. Only PBS was added to the basal side. After
the cells were incubated for 2 h under these conditions, 50 µL of sample from the apical side was quantitated
for the glucose concentration using the BioVision colorimetric glucose assay kit to determine the amount of
glucose liberated by the alpha-glycosidase.
2.11. Insulin secretion test
In order to determine the effects of the test compound on insulin secretion under normal or hyperglycemic
conditions, freshly passaged BTC6 cells were plated into 96-well microplates at 1 × 104 cells/well and incubated
under appropriate conditions for 2 days. At the end of that period, each well was washed twice with 200 µL
Krebs-ringer-bicarbonate-HEPES buffer (KRBH: 118, 4 mM NaCl, 4.75 mM KCl, 1.192 mM MgSO4 , 2.54
mM CaCl2 , 10 mM HEPES, 2 mM NaHCO3 , 0.1 % BSA). The cells were then incubated in 200 µL KRBH
buffer for 30 min at room temperature. Next, the medium was removed and the wells were incubated at room
temperature for 45 min in KRBH containing either a vehicle, positive control (1 µM glibenclamide), or test
compounds in the presence or absence of 33.3 mM glucose. After the incubation period, 20 µL of sample from
each well was transferred into a fresh 96-well plate and the amount of insulin in the medium was determined
using the highly-sensitive Millipore rat/mouse insulin colorimetric ELISA kit, as directed by the manufacturer’s
instructions.
2.12. Quantitative analyses of the transcripts in insulin signaling and glucose metabolism
Determination of the expression level of the genes involved in glucose metabolism and insulin signaling was
determined by treating the appropriate cell lines with the test compounds.
2.13. RNA isolation and cDNA synthesis
The total RNA was isolated from the cell lines using the RNeasy plus universal mini kit, following the manufac-
turer’s instructions, and was checked on a 1.5% (w/v) agarose gel stained with ethidium bromide and visualized
under ultraviolet light (DNR Bioimaging Systems Ltd., Neve Yamin, Israel). The RNA concentration and
purity were determined by measuring the optical density at ratios of 260/280 and 260/230 using a Nano Spec-
trophotometer (Maestrogen Inc., Taiwan, R.O.C.). RNA was reverse transcribed using the EasyScript™plus
cDNA Synthesis kit. The reaction mixture was incubated for 50 min at 50 ◦C, followed by termination by
heating at 5 min at 85 ◦C. The cDNA concentration was measured with a Nanodrop and distributed in aliquots
before storing at −80 ◦C.
2.14. qPCR quantification assays
The high-quality, ISO9001 certificated, custom-designed gene-specific primers had been synthesized by Gen-
Script (Piscataway, NJ, USA). These validated primers were used for profiling the differential gene expression
between separate treatment groups. Positive and negative controls, along with the housekeeping genes, were
applied for qPCR reactions for the normalization of target gene expression. After assuring the integrity, purity
and the quality of the cDNA, the whole volume of synthesized cDNA was used for the qPCR protocol. Enough
master mix, using KiloGreen 2X qPCR master mix, was prepared and run under the optimized thermal cycling
parameters on a Exicycler 96 Thermal Block (Bioneer, Corp., Daejeon, Korea).
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2.15. Statistical analyses
Statistical analyses were carried out by applying Student’s t-test using the GraphPad Prism 6.0 statistical
software package for Windows (GraphPad Software, Inc., CA, USA). Statistical significance was accepted as P
< 0.05 and the values were expressed as the mean ± standard deviation. The qRT-PCR data analysis web
portal (Qiagen, version 3.5) was applied. Values of the cycle threshold (Ct) obtained in the quantification were
used for calculations of the fold changes in mRNA abundance according to the 2−∆∆Ct method [25].
3. Results and discussion
The data obtained from the present study were given as the mean ± standard deviation of the repeated
experiments. Unless otherwise specified, all of the data were the average of at least 3 independent repeats of
triplet measurements. Molecular structures and the properties of the test compounds are given in Figure 2.
                          
Figure 2. Chemical structures of the test compounds, alysine A and alysine B.
3.1. The effect on cell viability
It was primarily aimed to determine the nontoxic doses. In preclinical toxicology studies, EC10 (the dose lethal
to 10% of the cell treated) represents a safe phase I trial starting dose and EC values for humans are best
estimated for human cell cultures. Therefore, the EC10 dose for alysine A and alysine B in the cell lines was
investigated by crystal violet staining. Figure 3 shows the cell viability, ranging from 0 to 1 mM for alysine A
and alysine B, respectively. As is obvious from Figure 3, the EC10 values were almost equal, and the average
of the calculated EC10 values for the different cell lines was used throughout the study for all of the cell lines,
i.e. 0.087 mM for alysine A and 0.075 mM for alysine B. Furthermore, the LDH leakage assay, based on the
measurement of the LDH activity in the extracellular medium, was performed to evaluate the effect of the
selected doses in all of the examined cell lines (Table 1).
Table 1. Effects of the test compounds on LDH activity in the extracellular medium of the cell lines.
Treatment LDH activity in the extracellular medium (mU/mL)BTC6 C2C12 3T3-L1 HepG2 Caco-2
Control 61.2 ± 7.67 52.0 ± 4.3 50.6 ± 6.48 78.2 ± 3.21 41.6 ± 5.43
Alysine A 57.4 ± 3.62 54.4 ± 0.72 58.8 ± 3.73 81.5 ± 1.80 47.8 ± 2.67
Alysine B 66.9 ± 3.68 49.6 ± 2.71 56.1 ± 5.58 62.7 ± 1.78 38.2 ± 3.39
3.2. Effect on the glucose uptake
The 3 cell lines were incubated with the test compounds, along with the control and positive control agents, and
then the remaining glucose concentration was determined in the extracellular medium. The cells were exposed
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Figure 3. Cytotoxic response of the different cell lines to alysine A (part A) and alysine B (part B). The dose-response
curve was used to estimate the EC10 values.
to 1 µM insulin, 1 µM metformin, and the test compounds for 2 h. Both test compounds significantly increased
the glucose uptake in the muscle and liver cell lines, whereas they showed little effect on the adipocytes (Table
2). The increment levels were higher with alysine A than with alysine B, and it was comparable and equal to
the increments exerted by both the insulin and metformin.
Table 2. Remaining glucose concentrations in the extracellular medium of the C2C12 muscle, HepG2 liver, and 3T3-L1
adipocyte cells after 2-h incubation with the test compounds.
Treatment Remaining glucose concentration in the extracellular medium (µg/mL)C2C12 HepG2 3T3-L1*
Control 12.4 ± 2.1 10.8 ± 2.8 13.4 ± 1.1
Metformin 1.84 ± 0.06a 2.05 ± 0.19a 7.30 ± 0.98a
Insulin 2.25 ± 0.10a 2.27 ± 0.07a 8.23 ± 0.62a
Alysine A 2.02 ± 0.19a 2.48 ± 0.13a 10.38 ± 1.22b
Alysine B 3.36 ± 0.40a 3.39 ± 0.48a 11.94 ± 1.40c
*Adipocyte differentiation of the preadipocyte cells were confirmed by observing 8.4-fold induction of the
G3PDH activity (preadipocytes: 4.94 ± 0.72 and differentiated adipocytes: 41.6 ± 2.68). a : P < 0.0001,
b : P< 0.001, c : P < 0.05.
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3.3. The effects on glucose utilization (glycogen content)
The effect of the test compounds, as well as the insulin on glucose utilization, in the C2C12 and HepG2 cells,
was assessed by measuring the amount of glucose stored as glycogen. The amount of intracellular glycogen
content was significantly increased by both alysine A and alysine B in both cell lines (Table 3). As seen in
the glucose uptake, the increments were higher with alysine A than alysine B, and it was even higher than the
insulin effect.
Table 3. Quantities of glycogen stored by the positive control and test compounds in the C2C12 muscle and HepG2
liver cell lines.
Treatment Intracellular glycogen concentration per 1.0 × 10
6 cells (µg/mL)
C2C12 HepG2
Control 0.232 ± 0.011 0.185 ± 0.015a
Insulin 0.534 ± 0.031a 0.305 ± 0.018a
Alysine A 0.717 ± 0.080a 0.591 ± 0.087a
Alysine B 0.507 ± 0.071a 0.432 ± 0.051a
a : P < 0.0001.
3.4. The effect on glucose transport
Via utilization of the confluent and differentiated Caco-2 cell monolayer, the impact of the test compounds on
the glucose uptake in the human Caco-2 cells was examined. The Caco-2 cell monolayers with intact, tight,
junctions displayed a consistent rate of glucose transport, as given in Table 4. Both alysine A and alysine B
exerted a significant stimulatory impact on the glucose transport over the Caco-2 monolayers. However, on the
contrary to the other effects seen with test compounds, the stimulation on the glucose uptake was almost as
twice as high with alysine B than with alysine A.
Table 4. Temporal glucose concentrations on the apical and basolateral surfaces of the Caco-2 cell monolayer treated
either with the positive control or test.
Treatment Glucose concentration (µg/mL) api-cal side
Glucose concentration (µg/mL)
basolateral side
0 min 30 min 60 min 0 min 30 min 60 min
Control 1.68 ± 0.08 1.70 ± 0.11 1.61 ± 0.04 0.13 ± 0.05 0.27 ± 0.17 0.50 ± 0.32
Insulin 1.63 ± 0.10 1.61 ± 0.03 1.61 ± 0.06 0.09 ± 0.00 4.55 ± 0.37a 6.79 ± 0.42a
Alysine A 1.70 ± 0.16 1.88 ± 0.02 1.65 ± 0.06 0.30 ± 0.00 3.80 ± 0.32a 7.29 ± 0.51a
Alysine B 1.73 ± 0.03 1.58 ± 0.09 1.69 ± 0.10 0.11 ± 0.01 3.53 ± 0.24a 14.06 ± 0.91a
a : P < 0.0001.
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3.5. The effect on glucose absorption (α-glucosidase activity)
The effect of the test compounds on the release of glucose by α -glucosidase was determined in the Caco-2 cell
monolayer. Neither of the test compounds showed inhibition of the sucrose hydrolysis activity of α -glucosidase
with the Caco-2 monolayer (Table 5).
Table 5. Glucose concentrations released by α -glycosidase at the apical surface of the Caco-2 cells in the presence of
the different test compounds.
Treatment Glucose concentration (µg/mL)
Control 0.080 ± 0.03
Alysine A 0.081 ± 0.08
Alysine B 0.084 ± 0.07
Glibenclamide was used as the positive control.
3.6. The effect on the insulin secretion
To study the effects of the test compounds on insulin secretion under normal or hyperglycemic conditions,
confluent BTC6 cells, in 96-well microplates, were used. Prior to the insulin secretion assay, the cells were
washed with KRBH and the culture media was changed, and the cells were then incubated with 8 mM glucose
KRBH media (normal conditions) or 33 mM glucose KRBH media (hyperglycemic conditions), and exposed to
experimental concentrations (Table 6) of the test compounds, as determined in the cell viability studies. After
exposure, the insulin content was subsequently determined. Neither of the test compounds affected the insulin
secretion under either of the normoglycemic or hyperglycemic conditions.
Table 6. Effect of alysine A and alysine B on the insulin secretion in the BTC6 cell.
Treatment Insulin Concentration (ng/mL)8 mM glucose 33 mM glucose
Control ND ND
Glibenclamide 4.1 ± 0.33 6.8 ± 0.71
Alysine A ND ND
Alysine B ND ND
ND: Not detectable.
3.7. The effect on the expression of the selected genes in glucose metabolism and insulin signaling
qPCR was applied to analyze the impact of the test compounds on the mRNA levels of the selected genes,
which are known to be important in the regulation of glucose metabolism and insulin signaling. A detailed
description of the genes and the primers used is given in Table S1. The expression levels of the genes were
examined primarily in the muscle, liver, and adipocyte cell lines, which are of the most important in glucose
homeostasis. In addition, several genes transcripts were also analyzed in the Caco-2 cell line, which were in
relation to the genes associated with glucose transport. Similarly, only the expression levels of the GLUT2 and
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insulin receptor substrate (IRS)-1 genes in the BTC6 cells were studied. Therefore, the genes expressed in the
relevant cells were examined in the appropriate cell line (Table 7).
Table 7. Effects of alysine A (AA) and alysine B (AB) on the expression levels of various genes involved in the insulin
pathway and glucose homeostasis in various cell lines.
3T3-L1 C2C12 HepG2 Caco-2 BTC6
AA AB AA AB AA AB AA AB AA AB
INSR 2.86 1.41 –1.25 –2.80 1.18 –1.01
IRS 1 –1.27 –1.56 1.16 –2.08 –1.86 –2.43 10.20 1.14
IRS 2 2.79 2.90 3.62 –1.10 –4.61 –5.12
PK 3.68 2.98 3.28 –2.28 5.04 2.87
PEPCK 14.12 2.33 64.45 1.69 4.17 2.38
GLUT4 4.50 2.40 2.97 –5.08
AKR 1.51 3.07 5.17 2.71 7.88 4.37
PI3K 5.84 –1.41
G6P 2.97 1.55 3.75 1.02 1.05 1.05
AG –3.82 –5.70
GLUT2 –1.52 –5.78 9.92 1.12
GLUT3 1.47
GLUT5 –2.29 –2.93
SLGT1 –4.52 –2.20
Cells shaded with light gray filling show significantly (P < 0.01) different values.
Expression levels were given as fold changes, normalized relative to the control.
Positive values indicate increases, and negative values indicate decreases.
For the in vivo antidiabetic studies, hyperglycemic animal models were utilized. In vivo studies are vital
and imperative to demonstrate the efficiency of new hypoglycemic agents and uncover the particular mechanism
of action of compounds. However, since there are numerous systems by which the blood glucose level is regulated,
and they are hard to control in animal models, various in vitro models arose as a more practical way to deal
with the screening of potential antidiabetic agents. These models were essential in overcoming potential ethical
issues, by reducing the unnecessary utilization of test animals, as well as surpassing financial constraints on
animal supply and care. Testing compounds that confirmed efficacy in the in vitro models, and later in the
animal models, were accepted as a more accurate strategy. Herein, a set of in vitro models was designed to
explore the actions and mechanisms of potential antidiabetic compounds [26–28].
The present research explored the in vitro antidiabetic properties of 2 novel compounds isolated and
characterized from endemic species Teucrium alyssifolium, with the aim of optimizing the techniques that were
required for their testing and determining their efficacy. The study was based on the fact that extracts from
Teucrium species are widely used as alternative and complementary medicine for T2DM. However, there is a
lack of scientific evidence for their efficacy [11,12,29]. To provide a detailed examination of glucose homeostasis,
appropriate cell lines, representing the specific metabolic pathways involved in glucose homeostasis, were used.
These cell lines were the C2C12 muscle, HepG2 liver, 3T3-L1 preadipocyte, Caco-2 epithelium, and pancreatic
βTC6 cells. Insulin, metformin (glucose utilization), and glibenclamide (insulin secretion) were used as the
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positive controls to compare the effects of the test compounds.
In studies to identify and detect new antidiabetic agents, compounds should be dosed such that they do
not exhibit toxic effects, as opposed to anticancer studies [30]. The doses to be used should be at levels that
will not cause contraindications to the in vivo systems and show no toxic effects, both in the model systems and
in advanced studies. For this reason, we identified EC10 as a safe phase I trial starting dose, and EC values for
humans are best estimated for human cell cultures. Moreover, the no observed effect level and lowest observed
effect level values were not detected with the cell lines [31]. These nontoxic values were used throughout the
studies. The LDH test also confirmed that the determined dose values of the test compounds used in the model
mechanisms did not exhibit toxic effects (Table 1). The LDH test confirmed that the selected doses did not
disrupt the integrity of the cells, and thus were nontoxic. These results also demonstrated that there was no
deterioration in the structural integrity of the cells.
When we examine the effects of alysine A and alysine B on the glucose uptake in the C2C12, HepG2,
and 3T3-L1 cells, we observed that both compounds increased the glucose uptake higher than the metformin
and insulin in all 3 cell lines (Table 2). Normally, at the physiological level, the muscle cell is the most highly
expressed by the GLUT4 transporter (gene expression/activity chart; BioGPS.org). In our experiments, the
observation of the highest glucose uptake in the adipocyte cells may have been due to an excessive increase
in GLUT4 expression level, while the preadipocyte cells were differentiated to adipocyte cells. Since glucose
uptake is an essential process for studying cell signaling and glucose metabolism [32,33], the strong positive
influences observed with alysine A and alysine B are important for their antidiabetic efficacy and are promising
for their expected activity in the in vivo system. It is possible to say that alysine A and alysine B are most
likely to act on GLUT4, since the common point among the 3 cell types is the accelerated glucose transport
into the cell by increasing the GLUT4 activity (GLUT4 translocates to the cell surface).
Our test compounds, on which the effects on glucose uptake were tested, also investigated the effects of
glucose on the glucose storage model, which is another important parameter of glucose homeostasis. For this
purpose, amounts of glycogen were determined in the model cell lines with glycogen storage capacity, the C2C12
muscle and HepG2 liver cell lines, when compared to the positive controls. In these experiments, results were
obtained in parallel with previous glucose uptake. It was observed that the alicyclic compounds alysine A and
alysine B significantly increased the amounts of stored glycogen in both cell lines, and significantly more than
the positive control insulin ratio. The results from this and previous glucose uptake assays strongly supported
that both compounds induced GLUT4 translocation through the protein kinase B (AKT) pathway by acting
on IR, and also activate the pathway of glycogenesis via AKT. Of course, further experimentation is needed to
support this model. It was also difficult to make a suggestion that such an effect was seen only in the liver cells
and to suggest a possible model mechanism.
New agents have been tested for their effect on the insulin section, since the glucose homeostasis was
maintained by a balance between insulin secretion and insulin action. For this reason, both alysine A and
alysine B were tested for their impact on insulin secretion under normal or hyperglycemic conditions using the
BTC6 cells. Neither of the test compounds affected the insulin secretion under either of the normoglycemic or
hyperglycemic conditions.
The key enzymes and proteins within the regulation of glucose homeostasis were investigated to explore
the antihyperglycemic impact and the mechanism of the test compounds. Both compounds increased the
expression of the genes that were activated by the insulin in the tested cell lines. As mentioned previously
above, 3 cell lines were investigated to obtain a detailed examination of glucose homeostasis. The insulin
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receptor (INSR), IRS2, protein kinase (PK), GLUT4, and phosphoinositide 3-kinase (PI3K) expression levels
were significantly increased in the 3T3-L1, C2C12, and HepG2 cells. These are significant genes involved in
the insulin signaling pathway, favoring the antidiabetic action [34,35]. IRS is the adaptor protein recruited
by the INSR and exhibits binding sites for diverse signaling companions. One of the signaling companions
is the PI3K, which has a major role in insulin functions. It mediates one of the most important metabolic
actions of insulin by translocating the GLUT4 from intracellular storage vesicles to the plasma membrane,
thereby increasing glucose uptake into the skeletal muscle and adipose tissue [32,36]. Therefore, the results of
the gene expression studies further confirmed our previous suggestion that these compounds induced GLUT4
translocation through the PI3K/AKT pathway by acting on IR, and also activated the pathway of glycogenesis
via AKT. However, the opposite expression pattern was displayed with phosphoenolpyruvate carboxykinase
(PEPCK), which is the key and regulatory enzyme in gluconeogenesis. The regulation of PEPCK is highly
complex, as its promoter region contains many binding sites for transcriptional regulators modulated by
glucagon, catecholamines, glucocorticoids, and insulin. It is also known that the repression of PEPCK gene
expression by glucose is insulin-independent, but requires glucose metabolism [37]. Therefore, further studies
using higher concentrations of glucose or pretreatment of the cells with glucose are required to resolve this
discrepancy. Nevertheless, the majority of the tested genes illustrated an expression pattern supporting the
antihyperglycemic impact of alysine A and alysine B. Aside from the expression of the transporter genes in the
Caco-2 cell line, the expression level of the genes in the muscle, liver, adipocyte, and pancreatic cells was in
favor of antidiabetic impact, contrary to a few genes like PEPCK.
As a conclusion, alysine A, and to lesser extent, alysine B, exercised significant and positive results on
glucose homeostasis, and is a natural and pleiotropic antidiabetic agent. The cyclic and aliphatic side chains
on the first ring of both compounds may have been responsible for the differences seen in the bioactivity of
the 2 compounds. Advanced in vivo studies are required to completely clarify the impact of this compound on
glucose homeostasis.
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Supporting material 
 
 All of the spectral data, including the 1D- and 2D-protons, and carbon NMR and X-ray 
spectra given below, were reported by [22]. 
 Extraction and isolation of the compounds: dried and powdered aerial parts of the plant 
(1.4 kg) were extracted with acetone at room temperature, evaporated under a vacuum, and 72 
g of a crude extract was obtained. The crude extract was chromatographed over silica gel using 
hexane, a gradient of ethyl acetate up to 100%, followed by ethanol. The collected fractions 
were combined after TLC control and further separated on small Si-gel and Sephadex LH-20 
columns, as well as on preparative TLC plates. From the preparative TLC separation, alysine A 
(105 mg) and alysine B (200 mg) were obtained. 
 Alysine A: obtained as colorless crystals; it had a molecular formula of C24H30O9, as 
determined by HR EIMS (m/z 462.1884). The structure was established based particularly on 
1H and 13C NMR spectroscopic techniques, including spin decoupling, heteronuclear 
correlation (HETCOR), heteronuclear multiple bond correlation (HMBC), and Selective 
Insensitive Nuclei Enhanced by Polarization Transfer (SINEPT) experiments, and confirmed 
by X-ray analysis. 
 Alysine B: isolated as a colorless crystalline compound. The FAB and HR EIMS 
indicated a molecular formula of C26H34O11 (m/z 522.2101). The structure was established 
based particularly on 1H and 13C NMR spectroscopic techniques, including 2D-NMR 
techniques. 
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Table S1. 1H and 13C NMR data of compounds alysine A and alysine B in CDCl3. 
NMR Data Alysine A Alysine B 
Position 1H 13C 1H 13C 
1 4.45 65.00 4.39 64.96 
2 2.28; 1.92 40.60 2.42; 1.92 37.86 
3 4.59 74.60 5.29 71.28 
4 - 63.27 - 71.37 
5 - 45.60 - 44.79 
6 3.80 75.40 3.92 75.93 
7 - 206.70 - 206.83 
8 - 53.91 - 53.49 
9 - 49.20 - 52.44 
10 2.31 45.73 2.40 42.02 
11 2.55 19.30 2.01; 2.42 18.94 
12 1.61; 2.84 33.62 1.61; 2.84 34.45 
13 - 116.30 - 116.54 
14 - 151.90 - 151.21 
15 6.24 110.44 6.22 110.25 
16 7.37 142.50 7.38 142.45 
17 1.34 19.19 1.42 18.08 
18 3.08; 2.62 49.20 4.22; 4.06 66.21 
19 4.27; 4.68 62.90 4.41; 5.15 65.50 
20 1.14 17.82 1.21 17.49 
CO - 170.13 - 169.97 
CH3 2.02 20.70 1.99 20.17 
CO - 169.70 - 169.59 
CH3 2.06 20.91 2.05 20.49 
CO - - - 169.59 
CH3 - - 2.08 20.76 
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Figure S1. 1H NMR Spectrum of alysine A (CDCl3). 
 
 
Figure S2. Enhanced 1H NMR spectrum of alysine A (CDCl3). 
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Figure S3. 13C NMR (BB) spectrum of alysine A (CDCl3). 
 
Figure S4. 1H–13C correlation (HETCOR) spectrum of alysine A. 
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Figure S5. Mass (EI) spectrum of alysine A. 
 
Figure S6. 1H NMR spectrum of alysine B (CDCl3). 
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Figure S7. 13C NMR (APT) spectrum of alysine B (CDCl3). 
 
 
Figure S8. 1H–13C correlation (HETCOR) spectrum of alysine B. 
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Figure S9. HRMS (EI) spectrum of alysine B. 
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Figure S10. X-ray spectra, crystal data, and data collection and refinement parameters of 
alysine A and alysine B. 
 
 
